Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Non-Current Deferred Tax Liability: 2017-2025

Historic Non-Current Deferred Tax Liability for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Sep 2025 value amounting to $30.1 million.

  • Ultragenyx Pharmaceutical's Non-Current Deferred Tax Liability changed negligibly% to $30.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.1 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $30.1 million for FY2024, which is negligibly% changed negligibly from last year.
  • Ultragenyx Pharmaceutical's Non-Current Deferred Tax Liability amounted to $30.1 million in Q3 2025, which was down 0.00% from $30.1 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Non-Current Deferred Tax Liability peaked at $33.3 million during Q1 2021, and registered a low of $30.1 million during Q4 2023.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median Non-Current Deferred Tax Liability value was $30.1 million (recorded in 2025), while the average stood at $30.5 million.
  • Data for Ultragenyx Pharmaceutical's Non-Current Deferred Tax Liability shows a maximum YoY declined of 5.08% (in 2023) over the last 5 years.
  • Ultragenyx Pharmaceutical's Non-Current Deferred Tax Liability (Quarterly) stood at $33.3 million in 2021, then declined by 4.92% to $31.7 million in 2022, then dropped by 5.08% to $30.1 million in 2023, then remained steady at $30.1 million in 2024, then remained steady at $30.1 million in 2025.
  • Its last three reported values are $30.1 million in Q3 2025, $30.1 million for Q2 2025, and $30.1 million during Q1 2025.